Elin Gunneriusson

This inventor holds 20 USPTO granted patents and 5 published patent applications, plus 5 CIPO patents and 11 EPO patents. Top assignees: Affibody Ab, General Electric Company, Ipc Research, LLC. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Elin Gunneriusson. Retrieved from https://idiyas.com/inventor/elin-gunneriusson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 (Patent Applications = 5)

% Patents Active = 95.0

CIPO Patents = 5 (Patent Applications = 3)

EPO Patents = 11 (Patent Applications = 19)

Average Co-Inventor Count = 5.5

ph-index = 5

Forward Citations = 49(Granted Patents)

Location History:

Lidingö, SE (2011)
Satlsjöbaden, SE (2018)
Saltsjobaden, SE (2012 - 2023)
Saltsjöbaden, SE (2015 - 2024)

Company Filing History:

General Electric Company

Swedish Orphan Biovitrum Ab (Publ)

patents

where one patent can have more than one assignee

Years Active: 2011-2026

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12653913 - HER2 BINDERS (2026-06-16),

2. 12083160 - Polypeptides binding to human complement C5 (2024-09-10),

3. 11633507 - HER2 binders (2023-04-25),

4. 11505576 - Polypeptides based on a scaffold (2022-11-22),

5. 11155596 - Polypeptide (2021-10-26),

6. 11123401 - Polypeptides binding to human complement C5 (2021-09-21),

7. 10894097 - HER2 binders (2021-01-19),

8. 10669314 - Polypeptide (2020-06-02),

9. 10562955 - Polypeptides (2020-02-18),

10. 10323066 - Neonatal Fc receptor binding dimer and methods of use (2019-06-18),

11. 10208128 - HER3 binding polypeptides (2019-02-19),

12. 10206975 - Polypeptides binding to human complement C5 (2019-02-19),

13. 10159760 - HER2 binders (2018-12-25),

14. 9975943 - Polypeptides (2018-05-22),

15. 9957330 - Polypeptides (2018-05-01),

Title: Elin Gunneriusson: Innovator in Biotherapeutics

Introduction: Elin Gunneriusson, based in Saltsjöbaden, Sweden, is a prominent inventor with a remarkable portfolio of 19 patents. His work predominantly focuses on biotherapeutics, significantly impacting the fields of medicine and diagnostics.

Latest Patents: Among his latest innovations, Gunneriusson has developed C5 binding polypeptides that specifically target the human complement C5. This invention includes a unique C5 binding motif, with a specified amino acid sequence, aimed at potential therapeutic applications for C5-related conditions. Additionally, he has contributed to the creation of imaging agents that incorporate isolated polypeptides conjugated with radionuclides and chelators, designed to bind specifically to HER2. These agents represent significant advances in diagnostic imaging techniques.

Career Highlights: Throughout his career, Gunneriusson has made substantial contributions to the field of biopharmaceuticals while working with notable companies such as Affibody and General Electric Company. His work has not only showcased his inventive prowess but has also propelled advancements in therapeutic and diagnostic methodologies.

Collaborations: Collaboration has been key to Gunneriusson's success. He has worked alongside esteemed colleagues such as Malin Lindborg and Joachim Feldwisch, which has facilitated the rapid development and application of his inventions in real-world contexts.

Conclusion: Elin Gunneriusson is a distinguished figure in the realm of innovative biopharmaceuticals. His numerous patents embody a commitment to advancing therapeutic solutions and diagnostic technologies, positioning him as a leading inventor in his field. With a robust portfolio and impactful collaborations, Gunneriusson continues to contribute significantly to the landscape of medical innovation.

Profile summary based on public USPTO records.